Compare Stocks → WARNING about the death of the U.S. dollar… (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKTXNASDAQ:ELABNASDAQ:MBRXNASDAQ:NH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.81-7.2%$1.51$1.08▼$5.50$14.34M0.9915,520 shs3,714 shsELABElevai Labs$0.64-4.5%$0.66$0.57▼$4.24$12.09MN/A1.01 million shs249,925 shsMBRXMoleculin Biotech$4.58-7.1%$5.02$4.28▼$15.75$10.59M1.8528,964 shs32,447 shsNHNantHealth$0.90+5.9%$0.74$1.24▼$9.75$6.93M1.8238,073 shs16,014 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics0.00%+25.81%+64.56%-15.22%-47.33%ELABElevai Labs0.00%-1.02%+1.36%-3.19%+66,809,900.00%MBRXMoleculin Biotech0.00%-0.40%+6.48%-46.65%-43.23%NHNantHealth0.00%-22.61%+43.74%+198.68%-36.94%WARNING about the death of the U.S. dollar… (Ad)Where do you turn during times of economic uncertainty? Many elites trust storing their wealth in gold (which has historically boomed when the dollar’s value has plummeted!)Get Colonial Metals' new Precious Metals Investment Guide.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AELABElevai LabsN/AN/AN/AN/AN/AN/AN/AN/AMBRXMoleculin Biotech2.2333 of 5 stars3.53.00.00.02.90.01.3NHNantHealthN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari TherapeuticsN/AN/AN/AN/AELABElevai LabsN/AN/AN/AN/AMBRXMoleculin Biotech3.00Buy$35.00664.19% UpsideNHNantHealthN/AN/AN/AN/ACurrent Analyst RatingsLatest NH, ELAB, AKTX, and MBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024MBRXMoleculin BiotechRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/26/2024MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $20.00(Data available from 5/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/AELABElevai Labs$1.71M7.07N/AN/A$0.22 per share2.91MBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/ANHNantHealth$67.68M0.10N/AN/A($30.72) per share-0.03Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/AN/AELABElevai Labs-$4.30M-$0.37N/A∞N/A-211.25%-225.32%-125.94%9/26/2024 (Estimated)MBRXMoleculin Biotech-$29.77MN/A0.00N/AN/AN/A-87.19%-68.91%8/9/2024 (Estimated)NHNantHealth-$67.78M-$7.65N/A∞N/A-94.67%N/A-39.82%N/ALatest NH, ELAB, AKTX, and MBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2024Q1 2024ELABElevai LabsN/A-$0.08-$0.08-$0.08N/A$0.62 million3/29/2024Q4 2023ELABElevai LabsN/A-$0.08-$0.08-$0.08N/A$0.70 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/AELABElevai LabsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ANHNantHealthN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.440.44ELABElevai Labs0.202.571.80MBRXMoleculin BiotechN/A3.513.51NHNantHealthN/A0.640.64OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%ELABElevai Labs22.22%MBRXMoleculin Biotech15.52%NHNantHealth4.50%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics61.80%ELABElevai LabsN/AMBRXMoleculin Biotech6.70%NHNantHealth61.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics97.92 million3.03 millionNot OptionableELABElevai Labs1818.89 millionN/AN/AMBRXMoleculin Biotech182.31 million2.16 millionNot OptionableNHNantHealth3267.70 million2.98 millionNot OptionableNH, ELAB, AKTX, and MBRX HeadlinesRecent News About These CompaniesMay 26 at 1:08 AM | americanbankingnews.comStockNews.com Begins Coverage on NantHealth (NASDAQ:NH)May 18, 2024 | americanbankingnews.comNantHealth (NASDAQ:NH) Now Covered by Analysts at StockNews.comMay 6, 2024 | complianceweek.comNantHealth welcomes chief legal officerMay 2, 2024 | keene.eduWorkWISE NHApril 23, 2024 | travel.usnews.com13 Most Romantic Getaways in New HampshireApril 23, 2024 | businesswire.comNantHealth Welcomes Marc Harrison as Chief Legal Officer to Executive TeamApril 15, 2024 | pharmaceutical-technology.comNantHealth gets grant for patient data exchange system with configurable sensors for healthcare providersApril 10, 2024 | finance.yahoo.comNantHealth Strengthens Product Leadership Team to Drive Innovation in Healthcare TechnologyApril 10, 2024 | businesswire.comNantHealth Strengthens Product Leadership Team to Drive Innovation in Healthcare TechnologyApril 8, 2024 | wmur.comEverything you need to know about April 8 total solar eclipse in New HampshireFebruary 18, 2024 | usatoday.comWill Nikki Haley give Donald Trump a run for his money in one-of-a-kind NH primary?February 17, 2024 | dispatch.comWill Donald Trump lock it up and knock Nikki Haley out. New Hampshire primary in 7 cartoons.January 21, 2024 | usnews.comWhat to Know About New Hampshire Before the PrimaryJanuary 11, 2024 | psychologytoday.comTherapists in Rochester, NHJanuary 6, 2024 | nypost.comNikki Haley slammed after saying NH voters ‘correct’ Iowa resultsJanuary 5, 2024 | foxnews.comFather of slain New Hampshire girl orchestrated savage plot to hide heinous crime: prosecutorsJanuary 3, 2024 | necn.comSeveral seriously injured, including infant, in New Hampshire highway crashDecember 27, 2023 | nypost.comChris Christie’s time, temper grows short in New HampshireDecember 27, 2023 | wmur.comState troopers investigating damage done to cemetery in New HampshireDecember 20, 2023 | wmur.comVideo: Areas of heavy rain, strong winds as storm veers away from NHNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesSeagate Technology Warns Cloud Demand is Heating Up April 30, 2024 10:10 AMView Seagate Technology Warns Cloud Demand is Heating Up CVS Health Stock Has a Silver Lining Called Value May 20, 2024 6:20 AMView CVS Health Stock Has a Silver Lining Called Value Robinhood Soars: Dissecting a Record-Breaking Q1 2024May 10, 2024 7:17 AMView Robinhood Soars: Dissecting a Record-Breaking Q1 2024Anheuser-Busch Continues Its Push to Retake the CrownMay 13, 2024 7:15 AMView Anheuser-Busch Continues Its Push to Retake the CrownIs Cigna Group the Nation's Best-Run Health Insurance Company?May 28, 2024 8:46 AMView Is Cigna Group the Nation's Best-Run Health Insurance Company?All HeadlinesCompany DescriptionsAkari TherapeuticsNASDAQ:AKTXAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Elevai LabsNASDAQ:ELABElevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.Moleculin BiotechNASDAQ:MBRXMoleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.NantHealthNASDAQ:NHNantHealth, Inc. engages in the provision of enterprise solutions that help businesses transform complex data into actionable insights. It is also involved in marketing solutions as a comprehensive integrated solution that includes clinical decision support, payer engagement solutions, data analysis, and network monitoring and management. The company was founded by Patrick Soon-Shiong on July 7, 2010 and is headquartered in Morrisville, NC. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.